Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Regulatory News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.778%)
Open: 18.25
High: 18.25
Low: 18.25
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Sep 2017 14:31

RNS Number : 0141Q
Destiny Pharma PLC
06 September 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

DESTINY PHARMA PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

HARGREAVE HALE LIMITED

City and country of registered office (if applicable)

BLACKPOOL, ENGLAND

4. Full name of shareholder(s) (if different from 3.)v

Name

DISCRETIONARY CLIENTS

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

04 SEPTEMBER 2017

6. Date on which issuer notified (DD/MM/YYYY):

06 SEPTEMBER 2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

11.7092

11.7092

41,651,770

Position of previous notification (if

applicable)

0

0

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BDHSP575

4,877,070

11.7092

SUBTOTAL 8. A

4,877,070

11.7092

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

All of the resulting shares are held in unit trusts operated by Marlborough Fund Managers Ltd, for whom Hargreave Hale Ltd manages the portfolio of investments on a discretionary basis.

 

The change in the percentage of shares held is due mainly to participation in the IPO/placing by Destiny Pharma plc, the shares from which were admitted to AIM on 04/09/2017.

 

Place of completion

HARGREAVE HALE LTD, BLACKPOOL, ENGLAND

Date of completion

06 SEPTEMBER 2017

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEADNKEAPXEFF
Date   Source Headline
2nd Dec 20222:48 pmRNSDirector Disclosure
23rd Nov 20227:00 amRNSAppointment of Corporate Broker
21st Nov 20222:20 pmEQSDestiny Pharma PLC 'leads the world' in new approach to preventing hospital infections
18th Nov 20221:16 pmRNSDirector Shareholding Amendment
15th Nov 20227:00 amRNSXF-73 advances to clinically enabling safety study
31st Oct 202211:06 amRNSSecond Price Monitoring Extn
31st Oct 202211:01 amRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSNotice of R&D Update Meeting
8th Sep 20227:00 amRNSInterim results for six months ended 30 June 2022
7th Sep 20227:03 amRNSPresenting at HC Wainwright Investment Conference
7th Sep 20227:01 amRNSPositive update from EMA on NTCD-M3 Phase 3 plans
5th Sep 20222:15 pmRNSExpiry of Share Options
22nd Aug 20227:00 amRNSNotice of Interim Results
28th Jul 20227:00 amRNSChair’s Investor Update
26th Jul 20227:00 amRNSPublication of new data on NTCD-M3
19th Jul 20227:00 amRNSPositive update from US FDA on XF-73 Phase 3
12th Jul 20227:00 amRNSGrant from the Cystic Fibrosis Foundation
7th Jul 20227:00 amRNSPublication of XF-73 drug synergy data
5th Jul 20227:00 amRNSNew XF-73 research programme
8th Jun 20227:00 amRNSGrant of share options
27th May 202211:56 amRNSResult of Annual General Meeting & Strategy Update
26th May 20227:00 amRNSBoard Changes
12th May 20227:00 amRNSLandmark NTCD-M3 data to be presented at Anaerobe
3rd May 20227:00 amRNSDestiny Pharma appoints Dr Yuri Martina as CMO
27th Apr 20223:34 pmRNSPosting of Annual Report and Notice of AGM
26th Apr 20223:30 pmRNSDirector/PDMR Shareholding
12th Apr 20227:00 amRNSAudited results for year ended 31 December 2021
4th Apr 20222:45 pmRNSNotice of Results
4th Apr 20222:37 pmRNSNotification of Major Holdings
31st Mar 20227:00 amRNSTo present data at ECCMID Congress
28th Mar 202211:30 amRNSResult of General Meeting and Total Voting Rights
25th Mar 20227:00 amRNSResult of Open Offer
22nd Mar 202210:30 amRNSExercise of Options and Total Voting Rights
8th Mar 202212:30 pmRNSFundraising
8th Feb 20227:00 amRNSPositive feedback from EMA on XF-73 Nasal gel Ph 3
1st Feb 20224:11 pmRNSExercise of Options and Total Voting Rights
1st Feb 20227:00 amRNSPositive data in XF-73 Dermal study with NIAID
31st Jan 20222:30 pmRNSExercise of Options and Total Voting Rights
25th Jan 20227:00 amRNSGrant of share options
24th Jan 20227:00 amRNSClinical and commercial opportunity of NTCD-M3
21st Jan 20227:15 amRNSDestiny Pharma Lancet Report
17th Jan 20227:00 amRNSStrategy/Company/Ops Update
21st Dec 20214:35 pmRNSExercise of Options and Total Voting Rights
17th Dec 20219:46 amRNSGrant of share options
15th Nov 20212:26 pmRNSDirectorate Change
4th Nov 20217:00 amRNSSAB Member Prof. Gerding is Keynote at C.diff Conf
18th Oct 20217:00 amRNSStudy gives strong support for potential of XF-73
27th Sep 20213:18 pmRNSDirector/PDMR Shareholding
27th Sep 20217:00 amRNSExpansion of clinical pipeline
9th Sep 20217:00 amRNSInterim results for six months ended 30 June 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.